UNSPSC 51401524: Fludiazepam

This classification denotes a benzodiazepine with the molecular formula C16H12ClFN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7F64A2K16Z, chemically known as 7-chloro-5-(o-fluorophenyl)-1,3-dihydro-1-methyl-2h-1,4-benzodiazepin-2-one but generally known as fludiazepam, which bears US NIH Compound Identifier 3369. European Medicines Agency schedules Fludiazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07681MIG.

UNSPSC 51401524 Fludiazepam is a Commodity code, but the recent state and local opportunities tagged to this code show minimal alignment with the specific pharmaceutical product named. The three recent solicitations involve naloxone and safe drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs and pharmacy benefit management (Texas Health and Human Services Commission), and multi-source generic pharmaceuticals and over-the-counter products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). None of these opportunities explicitly procure fludiazepam or match the benzodiazepine family described by the code's name. State and local purchasing offices appear to be using this code as a placeholder for broader pharmaceutical procurement activity, particularly around community health initiatives, prescription drug programs, and cooperative multi-state pharmaceutical sourcing, rather than for the specific controlled substance the code nominally describes.

The issuing bodies span health departments, county health systems, state HHS commissions, and multi-state cooperative purchasing alliances. Seminole County's IFB for naloxone and drug deactivation systems, posted June 30, 2026 with a due date of July 26, 2023, represents a direct-procurement approach for community health support with quarterly deliveries and a two-year initial term with one-year renewal option. The Texas Health and Human Services Commission's RFI (HHS0017013), posted April 3, 2026, seeks vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, functioning as market intelligence gathering ahead of a formal RFP. The Minnesota Multistate Cooperative Purchasing Alliance's RFP (S1070000015802), posted January 20, 2026 with proposals due March 26, 2026, establishes multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with pricing weighted at 75 percent and awards effective July 1, 2026. Recent activity appears concentrated in Florida, Texas, and the MMCAP member states (Minnesota and Oregon), though the code shows little recent activity directly tied to fludiazepam procurement.